Image
Image
Image

Empowering Wellness with Bioflor®

Your Natural Health Solution

Image

NATURAL SINGLE STRAIN YEAST

Unique Strain Designation with Proven Benefits

Bioflor®, with its unique strain Saccharomyces boulardii CNCM I-745, stands out as a single-strain yeast probiotic that has been extensively studied for its potential benefits in supporting gut health3. This unique strain designation is important because it allows researchers to specifically study the effects and properties of this particular strain. This ensures better control and consistency in both research and product development2.
It is clinically the most studied probiotic yeast, proving its efficacy in gut health 4,5. Its proven benefits make it a trusted choice for those seeking optimal digestive health.

It is clinically the most studied probiotic yeast, proving its efficacy in gut health 4,5. Its proven benefits make it a trusted choice for those seeking optimal digestive health.

Image

Conquering Antibiotics Side-effects

Not all probiotics are the same when it comes to taking them alongside antibiotics. Our Bioflor® offers a unique solution as a yeast-based probiotic that can be safely taken alongside antibiotics without contributing to antibiotic resistance6,7,8.

When antibiotics are taken, they have the potential to kill both harmful bacteria and beneficial bacteria, including bacteria-based probiotics6. This can result in a 25% reduction in gut microbiota diversity, disrupting the balance of gut flora and potentially leading to antibiotic resistance9. In some cases, bacteria-based probiotics can also transmit antibiotic-resistant genes, further exacerbating the issue.

In contrast, yeast-based probiotics like Bioflor® are not affected by antibiotics in the same way6,7. This makes Bioflor® a valuable option for individuals who require antibiotics but still want to maintain a healthy gut flora.

Image

Your Companion in Loose Stools and Antibiotics-Associated Dysbiosis

Bioflor®, with its unique strain Saccharomyces boulardii CNCM I-745, offers a distinctive solution for gut problems. It has proven to be effective in reducing the duration and frequency of loose stools in children10, as well as alleviating symptoms in adults11. This is achieved through various mechanisms12:

  • Degrade or bind to toxins, preventing toxin-induced increases in water in the gut
  • Stop harmful bacteria from attaching to the lining of the gut or invading gut cells
  • Keep up normal gut functioning by promoting the growth of beneficial gut microorganisms
  • Maintaining gut physiology and immune defenses

Bioflor® has been extensively proven to effectively protect gut flora and promote long-term health6,7.

Reference:

  1. Joly, F et al. Gut Microbiota: A full-fledged organ. 2017. Marteau, P and Dore J (Ed.). Paris: John Libbey Eurotext.
  2. Guarner et al. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. February 2017. https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english. Last accessed 14th November 2019.
  3. More MI, and Swidsinski, A. Clinical and experimental gastroenterology. 2015; 8: 237.
  4. Szajewska H, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):232-247. doi: 10.1097/MPG.0000000000003633.
  5. Bioflor® (Saccharomyces boulardii). [Prescribing Information]
  6. Neut C, Mahieux S, Dubreuil LJ. Antibiotic susceptibility of probiotic strains: Is it reasonable to combine probiotics with antibiotics?. Med Mal Infect. 2017;47(7):477-483. doi:10.1016/j.medmal.2017.07.001
  7. BIOCODEX. Saccharomyces boulardii CNCM I-745® - Company Core Data Sheet. 2021. Reference: I.2963/EN.
  8. Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M, et al. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Curr Microbiol. 2020;77(9):1987-1996. doi:10.1007/s00284-020-02053-9
  9. Panda S, et al. Short-term effect of antibiotics on human gut microbiota. PloS one. 2014; 9(4): e95476
  10. Feizizadeh S, Salehi-Abargouei A, and Akbari V. Efficacy and safety of Saccharomyces boulardii. Pediatrics. 2014. 134(1): e176-e191.
  11. Höchter, W, Chase D and Hagenhoff G. Münch Med Wochenschr. 1990; 132: 188-92
  12. McFarland, LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World journal of gastroenterology: WJG. 2010; 16(18): 2202.
AD-20240716-01